Cizzle Biotechnology Expands CIZ1B Lung Cancer Blood Test Commercially in Texas Following CLIA Certification

Cizzle's CIZ1B Biomarker Technology and Clinical Validation Process

Cizzle Biotechnology has developed the CIZ1B biomarker into a minimally invasive blood test aimed at enabling early lung cancer detection. The CIZ1B biomarker is a naturally occurring variant of the nuclear protein CIZ1, associated with maintaining epigenetic integrity and strongly linked to early-stage lung cancer presence. This test detects the biomarker in small blood samples, offering a cost-effective diagnostic tool for licensed healthcare providers. This approach addresses a critical clinical need, as early lung cancer detection significantly improves patient outcomes and survival rates.

The validation process culminated in June 2026 when the CIZ1B test completed laboratory validation and received CLIA accreditation at OmniHealth Diagnostics, a regulated US laboratory partner. CLIA accreditation is mandatory for clinical laboratory tests in the US, ensuring compliance with stringent quality and accuracy standards. This regulatory achievement enabled the transition from limited targeted sales to full commercial availability, allowing licensed US healthcare providers to order the test.

Strategic Texas Market Selection and Initial Commercial Deployment

Cizzle Bio Inc, holding exclusive rights to commercialize the CIZ1B test in the US, Canada, and the Caribbean, chose Dallas-Fort Worth and San Antonio for its initial full commercial expansion. These metropolitan areas were strategically selected based on large lung cancer at-risk populations, strong physician networks capable of supporting test adoption, and their importance to the company’s wider North American commercialization strategy. These Texas markets represent a significant target population and provide an optimal foundation to demonstrate rapid market uptake and operational scalability.

The commercial launch follows Cizzle Bio’s initial commercial readiness program, which included logistics planning, supply chain setup, and limited targeted sales to validate market demand and operational workflows. Allan Syms, Executive Chairman of Cizzle Biotechnology, stated that with accreditation and infrastructure in place to manage anticipated demand, the company is focusing on marketing and deployment. Starting full commercial operations in these populous Texas regions is intended as a model for expansion into other US states, Canada, and Caribbean territories shortly.

Licensing Framework and North American Partnership Model

Cizzle Biotechnology uses a royalty-bearing licensing model for its proprietary diagnostics, granting exclusive North American and Caribbean rights to Cizzle Bio Inc. This structure enables Cizzle Biotechnology to maintain UK operations while leveraging Cizzle Bio’s local market expertise, regulatory knowledge, and commercialization infrastructure in North America. Cizzle Bio, based in Texas, focuses on biomarker-based blood tests for cancer diagnostics, starting with early detection of lung and gastric cancers. The licensing agreement provides Cizzle Biotechnology with royalty revenue based on test sales, creating ongoing financial linkage to market success without direct US operational involvement.

Beyond Texas, Cizzle Biotechnology plans to increase physician access to the CIZ1B test through additional CLIA-certified laboratories across the US in the coming months. This multi-partner strategy aims to geographically distribute testing capacity, reduce sample processing bottlenecks, and enhance accessibility nationwide. Cizzle Bio also holds exclusive global rights to commercialize the DEX-G2 biomarker gastric cancer test alongside the lung cancer test in US clinical settings, indicating a longer-term diagnostic pipeline.

Regulatory Context and Importance of CLIA Accreditation

The Clinical Laboratory Improvement Amendments (CLIA) provide the primary regulatory framework for laboratory-developed tests (LDTs) and clinical laboratory testing in the US. CLIA accreditation certifies that laboratories and their tests meet federal quality, accuracy, and reliability standards, essential for clinical use by healthcare providers. OmniHealth Diagnostics, the CLIA-certified lab partner for the CIZ1B test, supplies the regulated infrastructure required for test availability to licensed US providers. This accreditation removes a major regulatory barrier and signals rigorous validation and compliance with safety and efficacy standards.

The swift transition from laboratory validation in June 2026 to commercial availability in July 2026 underscores the company’s ability to execute promptly after regulatory approval. CLIA accreditation does not require US Food and Drug Administration (FDA) pre-market approval for most LDTs, enabling faster market entry than FDA-regulated devices. However, this pathway places responsibility on labs and providers to ensure proper test use and interpretation. The company’s plan to collaborate with multiple CLIA-certified labs nationwide reflects awareness of regional capacity constraints and the need for distributed laboratory networks for broad market penetration.

Focus on At-Risk Populations and Clinical Adoption Strategy

The Dallas-Fort Worth and San Antonio areas encompass large populations with risk factors for lung cancer, including current and former smokers and individuals with occupational or environmental exposures. These metros have extensive physician networks across oncology, primary care, and pulmonology specialties, critical for clinical adoption of new diagnostics. Cizzle Bio’s emphasis on strong physician relationships and medical education indicates a strategy prioritizing healthcare provider engagement over direct-to-consumer marketing or broad screening campaigns.

Texas’s strategic importance to the company’s commercialization plans reflects its role as both a revenue source and a proof-of-concept market for expansion. Success in these areas, measured by test volume, physician engagement, and patient outcomes, will support scaling to other US states, Canada, and Caribbean territories where Cizzle Bio holds licenses. The company anticipates significant near-term sales growth if adoption meets expectations.

Cizzle Biotechnology’s Market Position and Historical Background

Cizzle Biotechnology Holdings plc was admitted to the Official List and Main Market of the London Stock Exchange in May 2021, establishing its status as a publicly regulated UK company. The company focuses on early cancer detection R&D, with the CIZ1B biomarker as its leading commercial product. Its business model centers on developing proprietary diagnostics and licensing them to regional partners for royalty revenue, avoiding direct operation of clinical labs or healthcare networks globally.

Cizzle collaborates with commercial partners and cancer care centers of excellence to support clinical adoption and commercialization. This approach leverages academic medical centers and specialist facilities to validate clinical utility and build provider confidence in the CIZ1B test. The lung cancer blood test represents a key step toward monetizing intellectual property and transitioning from R&D to active market participation and revenue generation.

Commercial Expansion Timeline and Geographic Scope

The Texas launch represents the initial phase of Cizzle Bio’s US commercialization strategy. The company expects to expand physician access through additional CLIA-certified labs across the US in coming months, though specific timelines, regions, and partner numbers remain undisclosed. This phased rollout allows operational capacity management, market demand validation by region, and commercialization process refinement based on early Texas results.

Beyond the US, the licensing agreement grants Cizzle Bio exclusive commercialization rights in Canada and the Caribbean. Executive Chairman Allan Syms identified these regions as short-term expansion targets following US market establishment. The licensing scope covers a substantial population base and multiple healthcare systems with varied regulatory environments, though no detailed timelines or milestones were provided.

Revenue Model and Financial Impact for Cizzle Biotechnology

Cizzle Biotechnology’s revenue from the CIZ1B test derives from a royalty-based licensing agreement with Cizzle Bio Inc, receiving ongoing payments tied to test sales volume rather than direct sales revenue. The announcement does not disclose royalty rates, minimum commitments, or financial thresholds for additional compensation. This model offers scalable revenue aligned with market adoption but depends on successful commercialization by the licensee to generate meaningful returns for shareholders.

The commencement of commercial sales in Texas marks the start of revenue generation, though timing and scale of royalties hinge on Cizzle Bio’s sales performance and physician adoption rates. Investors will likely monitor future disclosures on test volumes, geographic expansion, and revenue contributions from the licensing deal. No financial guidance or revenue projections were shared regarding the Texas launch or broader US commercialization.

Competitive Landscape and Early Cancer Detection Market Trends

Early detection blood tests for lung cancer are a rapidly growing segment within global cancer diagnostics, driven by biomarker advancements, increased screening awareness, and demand for cost-effective tools. Cizzle’s CIZ1B test competes with established multi-cancer and lung cancer-specific diagnostics. The company highlights the test’s non-invasive nature, cost advantages over imaging-based screening, and suitability for broad healthcare provider use without specialized oncology infrastructure.

Market dynamics include evolving clinical guidelines on screening eligibility, regional smoking prevalence, and provider adoption of new diagnostics. The chosen Texas markets, with high lung cancer incidence and experienced providers, offer favorable conditions for adoption. Success depends on differentiating the CIZ1B test through clinical validity, ease of use, cost-effectiveness, and physician acceptance relative to alternative diagnostics.

Outlook and Investor Considerations

Investors can anticipate future updates on several fronts: activation of additional CLIA-certified labs to broaden US geographic coverage; test adoption metrics, physician ordering volumes, and patient outcomes from Texas markets as indicators of market validation; announcements regarding expansion into Canada and Caribbean markets; publication of clinical and health economic data supporting the test’s utility and cost-effectiveness; and progress on the DEX-G2 gastric cancer diagnostic pipeline commercialized by Cizzle Bio, representing a longer-term revenue opportunity.